DLAT and primary biliary cholangitis: This concept of ‘bystander suppression’ has been demonstrated in a number of mouse models of autoimmune disease and murine AILD—in which tolerance-inducing MHC-II carrying nanoparticles loaded with liver antigen CYP2D22 successfully induced antigen-specific tolerance to CYP2D22 and also prevented pathogenic immune responses to PBC-related liver antigen PDCE-2 [135].